Efficacy of Equoral in Prophylactic Immunosuppression after De Novo Kidnex Transplantation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F07%3A00004195" target="_blank" >RIV/61989592:15110/07:00004195 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of Equoral in Prophylactic Immunosuppression after De Novo Kidnex Transplantation

Popis výsledku v původním jazyce

Cyclosporin A is a well-known calcineurin inhibitor that has been used for prophylactic immunosuppression after organ transplantation. The aim of this stud was to evaluate the eflicacy and safety of a new genetic cyclosporin formulation, Equoral (Teva Pharmaceuticals), in the treatment of de novo renal transplant recipients. Methods:Twenty cadaveric-donor renal transplant recipients between 23 abd 71 years of age at the tie of transplantation (mean age 52+-12,5 years) wete folkowed for 12 montis to determie if the gratts functioned and ion there were rejection attacks and side effects. In addition to cyclosporin, all patients received mycophenolate mofetil (CellCept) and Prednisone (Prednison). Results. Mean serum creatinine level decreased significantly after transplantation. in 6 of the 20 patients observed. 7 biopsies showed acute rejection episodes (35%) Over the 12-month post-transplant periodm,´, all patients showed stable graft function, with a mean serum creatinine level of 202

Název v anglickém jazyce

Efficacy of Equoral in Prophylactic Immunosuppression after De Novo Kidnex Transplantation

Popis výsledku anglicky

Cyclosporin A is a well-known calcineurin inhibitor that has been used for prophylactic immunosuppression after organ transplantation. The aim of this stud was to evaluate the eflicacy and safety of a new genetic cyclosporin formulation, Equoral (Teva Pharmaceuticals), in the treatment of de novo renal transplant recipients. Methods:Twenty cadaveric-donor renal transplant recipients between 23 abd 71 years of age at the tie of transplantation (mean age 52+-12,5 years) wete folkowed for 12 montis to determie if the gratts functioned and ion there were rejection attacks and side effects. In addition to cyclosporin, all patients received mycophenolate mofetil (CellCept) and Prednisone (Prednison). Results. Mean serum creatinine level decreased significantly after transplantation. in 6 of the 20 patients observed. 7 biopsies showed acute rejection episodes (35%) Over the 12-month post-transplant periodm,´, all patients showed stable graft function, with a mean serum creatinine level of 202

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Transplantation

ISSN

0041-1337

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

602-607

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—